Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "USP"

418 News Found

Amring Pharmaceuticals launch Isoproterenol Hydrochloride Injection USP
News | August 10, 2021

Amring Pharmaceuticals launch Isoproterenol Hydrochloride Injection USP

The drug is indicated for mild and transient episodes of heart block


Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
News | June 02, 2021

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.


Bharat Parenterals receives license for Favipiravir Oral Suspension
News | May 23, 2021

Bharat Parenterals receives license for Favipiravir Oral Suspension

The product patent has been already filed under fast track approval


Lupin launches penicillamine tablets USP
News | March 04, 2021

Lupin launches penicillamine tablets USP

Penicillamine Tablets USP, 250 mg (RLD: Depen) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT December 2020).


Quest Diagnostics’ study confirms accuracy of blood tests for Alzheimer’s disease diagnosis
R&D | October 30, 2025

Quest Diagnostics’ study confirms accuracy of blood tests for Alzheimer’s disease diagnosis

Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging


AstraZeneca Pharma India to launch Sodium Zirconium Cyclosilicate powder in Nov 2025
News | October 16, 2025

AstraZeneca Pharma India to launch Sodium Zirconium Cyclosilicate powder in Nov 2025

Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) is indicated for the treatment of hyperkalaemia in adult patients


FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder
Drug Approval | October 11, 2025

FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder

UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults


Lonza expands cell and gene therapy portfolio
Biotech | October 07, 2025

Lonza expands cell and gene therapy portfolio

Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies


FDA approves Alembic’s Paroxetine ER tablets
Drug Approval | September 26, 2025

FDA approves Alembic’s Paroxetine ER tablets

Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder


Evonik launches MaxiPure Polysorbate 80 for injectable drug formulations
News | September 25, 2025

Evonik launches MaxiPure Polysorbate 80 for injectable drug formulations

Ultra-high purity surfactant for biologics and parenteral drug formulations